37.31
price down icon1.63%   -0.62
after-market Handel nachbörslich: 38.10 0.79 +2.12%
loading

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

pulisher
Jul 23, 2025

What drives Cytokinetics Incorporated stock priceRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Cytokinetics Incorporated Stock Analysis and ForecastUnbelievable profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Cytokinetics Incorporated stockRapid wealth creation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Cytokinetics Awards 220,000 Shares in Employee Stock Grants at $38.68 Strike Price - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks

Jul 18, 2025
pulisher
Jul 15, 2025

Cytokinetics CEO Makes a Significant Stock Move! - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com Australia

Jul 15, 2025
pulisher
Jul 15, 2025

Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cytokinetics Incorporated stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Cytokinetics Incorporated stock price move sharplyDaily Swing Candidates - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Jul 14, 2025
pulisher
Jul 11, 2025

CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 10, 2025

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times

Jul 10, 2025
pulisher
Jul 10, 2025

Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Quiver Quantitative

Jul 10, 2025
pulisher
Jul 10, 2025

Major Clinical Trial Results: Cytokinetics Reveals New Aficamten Data vs Metoprolol in HCM Treatment - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire

Jul 09, 2025
pulisher
Jul 06, 2025

Cytokinetics (CYTK): Balancing Optimism and Caution in Aficamten's High-Stakes Journey - AInvest

Jul 06, 2025
pulisher
Jul 01, 2025

CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jul 01, 2025
pulisher
Jun 27, 2025

CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire

Jun 27, 2025
pulisher
Jun 25, 2025

Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress - Yahoo.co

Jun 25, 2025
pulisher
Jun 23, 2025

11 Best Most Active Stocks To Buy According to Analysts - Insider Monkey

Jun 23, 2025
pulisher
Jun 20, 2025

Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth? - Smartkarma

Jun 20, 2025
pulisher
Jun 19, 2025

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com

Jun 19, 2025
pulisher
Jun 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 18, 2025
pulisher
Jun 17, 2025

Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 15, 2025

Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook By Investing.com - Investing.com India

Jun 15, 2025
pulisher
Jun 14, 2025

Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times

Jun 10, 2025
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):